Regenxbio (RGNX) Misses Q3 EPS by 29c; Reports $533.5M of Cash and Cash Equivalents
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/20/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Far-left party wins Berlin election, pledging to nationalise housing
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
REGENXBIO Reports Third Quarter 2021 Financial Results and Operational Highlights
November 2, 2021 4:05 PM EDTROCKVILLE, Md., Nov. 2, 2021 /PRNewswire/ --
Announced eye care collaboration with AbbVie to develop and commercialize RGX-314 AbbVie and REGENXBIO form a strategic partnership combining eye care and gene therapy expertise REGENXBIO to receive $370 million upfront payment Transaction expected to close by end of 2021, subject to satisfaction of customary closing conditions, including applicable regulatory approvals Presented positive initial data from RGX-314 Phase II trials for the treatment of wet AMD and diabetic retinopathy using in-office suprachoroidal delivery  ... More